Search results
Results from the WOW.Com Content Network
Following the news release, shares of the company closed at $43.12, denoting a slight decline in Friday’s trading session. ... NeoGenomics, Inc. (NEO), one of the foremost providers of cancer ...
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
NeoGenomics first received state and national-level laboratory certifications in 2002. Three years later in 2005, the company developed a technical-only service model using FISH. In 2013, the company launched its sequencing platform [3] and was listed on the Nasdaq Stock Market as NEO. In 2014, NeoGenomics launched molecular tests including BTK ...
For premium support please call: 800-290-4726 more ways to reach us
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! In 2009 Doug VanOort was appointed CEORead More...
NeoGenomics (NEO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
The big shareholder groups in NeoGenomics Inc (NASDAQ:NEO) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders own a ...